NEW YORK (GenomeWeb News) – After years in development, a handheld point-of-care molecular diagnostic device from QuantuMDx is poised to hit the market next year with malaria and tuberculosis as its initial target markets, a company executive said last week on the sidelines of the 32nd Annual JP Morgan Healthcare Conference in San Francisco.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.